Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Conditions:   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage II Follicular Lymphoma;   Ann Arbor Stage II Marginal Zone Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Follicular Lymphoma;   Ann Arbor Stage III Ma rginal Zone Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Follicular Lymphoma;   Ann Arbor Stage IV Marginal Zone Lymphoma;   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   Indolent Non-Hodgkin Lymphoma Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Parsaclisib;   Biological: Pegfilgrastim;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials